CITIUS ONCOLOGY, INC. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities The information regarding our equity compensation plans required by this Item is found in Item 12 of this report. Market Information Our common stock trades on The Nasdaq Capital Market under the symbol “CTOR.” Holders of Common Stock Based upon information furnished by our transfer agent, as of December 17, 2025, we had approximately 5 stockholders of record of our common stock. However, because many of the shares of our common stock are held by brokers and other institutions on behalf of stockholders, we believe there are substantially more beneficial holders of our common stock than record holders. Dividends We have never paid dividends on our common stock. We intend to follow a policy of retaining earnings, if any, to finance the growth of our business and do not anticipate paying any cash dividends in the foreseeable future. The declaration and payment of future dividends on the common stock will be at the sole discretion of our Board and will depend on our profitability and financial condition, capital requirements, statutory and contractual restrictions, future prospects and other factors deemed relevant by the Board. Recent Sales of Unregistered Securities During the year ended September 30, 2025, we did not issue or sell any unregistered securities not previously disclosed in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K. Issuer Purchases of Equity Securities We did not make any purchases of our common stock during the three months ended September 30, 2025, which is the fourth quarter of our fiscal year. Item 6. [Reserved] 49